Bristol Myers Antibody Combo Significantly Improves Progression-Free Survival vs. Opdivo in Melanoma

 First presentation of Phase 3 data from a trial evaluating a LAG-3-blocking antibody

Fixed-dose combination of relatlimab and nivolumab demonstrated statistically significant and clinically meaningful benefit over Opdivo monotherapy, an established standard of care

Data demonstrate inhibiting LAG-3 together with PD-1 helps improve outcomes for patients

Data to be featured in an oral presentation during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

https://www.yahoo.com/now/bristol-myers-squibb-announces-lag-210000199.html